NCT01157260

The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Ewha Womans University · Academic / Other
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Indoxyl sulfate (IS) is a uremic toxin that accelerates the progression of chronic kidney disease (CKD). AST-120 (Kremezin®; Kureha Corporation, Tokyo, Japan) removes indole, which is the precursor of IS, in the intestine, and reduces the accumulation of IS. This drug has been shown to retard the deterioration of renal function in CKD patients through reducing the levels of IS. IS was reported to promote aortic calcification and stimulate the proliferation of vascular smooth muscle cells (VSMC). IS also inhibits endothelial proliferation and wound repair. With this background, the investigators will performed the study whether AST-120 improve the endothelial dysfunction in CKD patients.

Detailed description

The purpose of this study is to examine whether Kremezin, Indoxyl sulfate lowering agent improve endothelial dysfunction in stage 3,4 chronic kidney disease patients

Conditions

• Kidney Failure, Chronic

Interventions

Type	Name	Description
DRUG	Kremezin	AST-120 2g three times a day

Timeline

• Start date: 2010-09-01
• Primary completion: 2011-08-01
• Completion: 2011-12-01
• First posted: 2010-07-07
• Last updated: 2010-07-07

Locations

1 site across 1 country: South Korea